TP53 and cancer: In fact, in comparison to other p73-targeting agents such as SIMPs31 and RETRA32, known to target p73 by disrupting mutant-p53:p73 inhibited complex hence effective only in p53-mutant cancer cells, BITC is more beneficial, as BITC not only disrupts mutant-p53:p73 association but also effectively upregulates p73 expression.